NCT05035953 is a Phase 2 clinical trial of Edaravone Dexborneol in Stroke, Ischemic, sponsored by Huashan Hospital.

Who is sponsoring NCT05035953?

NCT05035953 is sponsored by Huashan Hospital.

What drugs are being tested in NCT05035953?

Interventions in NCT05035953: Edaravone Dexborneol, Placebo.

What condition does NCT05035953 study?

NCT05035953 studies Stroke, Ischemic.

Is NCT05035953 still recruiting?

NCT05035953 is currently status unknown. Last updated 5 September 2021.

Last reviewed 2021-09-05 · How we verify

NCT05035953

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Thrombolysis Combined With Edaravone Dexborneol on Hemorrhagic Transformation for Acute Ischemic Stroke

Status unknown Phase 2 Last updated 5 September 2021

What this trial tests

Phase 2 trial testing Edaravone Dexborneol in Stroke, Ischemic in 200 participants. Status unknown.

Timeline

13 September 2021

Primary endpoint
13 September 2023

13 March 2024

Quick facts

Lead sponsor	Huashan Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	13 September 2021
Primary completion	13 September 2023
Estimated completion	13 March 2024

Drugs / interventions tested

Edaravone Dexborneol — full drug profile →
Placebo

Conditions studied

Stroke, Ischemic — all drugs for Stroke, Ischemic →

Sponsor

Huashan Hospital

Who can join

Adults 18 to 80, any sex, with Stroke, Ischemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received thrombolysis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke.
Wicks EE, Ran KR, Kim JE, Xu R, et al · · 2022 · cited 68× · PMID 35795678 · DOI 10.3389/fimmu.2022.897022

Verify or expand the search:

Other trials of Edaravone Dexborneol

Trials testing the same drug.

NCT07454473 — Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study · Phase 4 · recruiting
NCT05121883 — Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke · unknown
NCT04817527 — Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows · Phase 2 · unknown
NCT04714177 — Edaravone Dexborneol for Treatment of Hypertensive Intracerebral Hemorrhage · Phase 2 · unknown

Other recruiting trials for Stroke, Ischemic

Currently open trials in the same condition.

NCT07456956 — HIIT vs MCIT for Stroke-Related Sarcopenia in Ischemic Stroke · NA · recruiting
NCT06658197 — Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke · Phase 3 · recruiting
NCT07282041 — Role of GLP1 RA Dulaglutide on Severe Intracranial Atherosclerosis · Phase 2, PHASE3 · recruiting
NCT07135089 — Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban · Phase 3 · recruiting
NCT07047014 — Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Tenecteplase in Medium Vessel Occlusion (MeVO) for Acute Ische · Phase 3 · recruiting

Other Huashan Hospital trials

Trials by the same sponsor.

NCT07469735 — Vorasidenib Guided by AGX PET in Recurrent/Low-grade Glioma · NA · not yet recruiting
NCT07364487 — This is an Open-Label Study to Assess the Safety and Efficacy of GC012F in Patients With Multiple Sclerosis · EARLY_PHASE1 · withdrawn
NCT07369830 — The Impact of Probiotic Intervention on the Gut Microbiota and Bowel Function · NA · recruiting
NCT07185373 — Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL · Phase 2, PHASE3 · not yet recruiting
NCT07075029 — RSV in Acute Respiratory Infection Surveillance Among Community-Dwelling Elderly Aged ≥50 Years in China · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05035953 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Huashan Hospital
Last refreshed: 5 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05035953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing